Facebook
X
LinkedIn
ForwardIndolent Lymphomas: Radiation Oncology Considerations (PRO 07)
Recent studies have led to radical change in concepts when considering Radiation Therapy for indolent lymphomas. This activity reviews clinical and practical updates in regards to dose considerations, patient selection and radiation techniques for this heterogenous group of patients. Considerations within a multi-disciplinary team environment are also discussed.
Target Audience
This activity is designed to meet the interests of medical oncologists, radiation oncologists, pathologists and residents.
Learning Objectives
Upon completion of this activity, participants should be able to do the following:
- Differentiate patients that are appropriate for radiation therapy and which of these patients may benefit for ultra low dosing.
- Understand the toxicity reduction efforts with the various tools at our disposal including dose considerations and techniques.
- Elizabeth A. Kidd, MD, is employed by Stanford University.
- Taylor Jenkins, MD, is employed by Virginia Commonwealth University.
- Susan Elizabeth Gueble, MD, PhD, is employed by Yale School of Medicine.
- Junzo P. Chino, MD, FASTRO, is employed by Duke University Medical Center.
- Malolan S. Rajagopalan, MD, MBA, is employed by Radiology, Inc.
All relevant financial relationships have been mitigated.
The person(s) above served as the developer(s) of this activity. Additionally, the Annual Meeting Steering Committee had control over the content of this activity.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
Available Credit
- 1.25 AMA PRA Category 1 Credit™
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.